Author:
Araste Fatemeh,Ebrahimizadeh Walead,Rasooli Iraj,Rajabibazl Masoumeh,Mousavi Gargari Seyed Latif
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Biotechnology,Bioengineering,Applied Microbiology and Biotechnology
Reference15 articles.
1. Ahlskog J, Schliemann C, Marlind J, Qureshi U, Ammar A, Pedley R, Neri D (2009) Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Brit J Cancer 101:645–657
2. Atkins M, mcdermott D, Regan M, Stanbridge E, Upton M, Youmans A, Febbo P, Lechpammer M, Signoretti S (2004) Carbonic anhydrase IX (CAIX) expression predicts for renal cell cancer (RCC) patient response and survival to IL-2 therapy. In: Proceeding American Society of Clinical Oncology, vol 14S. p 4512
3. Brekke O, Loset G (2003) New technologies in therapeutic antibody development. Curr Opin Pharmacol 3:544–550
4. Brennan DJ, Jirstrom K, Kronblad A, Millikan RC, Landberg G, Duffy MJ, Ryden L, Gallagher WM, O’Brien SL (2006) CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res 12:6421–6431
5. Dubois L, Douma K, Supuran CT, Chiu RK, van Zandvoort MA, Pastoreková S, Scozzafava A, Wouters BG, Lambin P (2007) Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother Oncol 83:367–373
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献